InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,870.62
(
-1.32%
)
US TECH 100
19,880.00
(
-2.30%
)
Dow Jones
43,444.99
(
-0.70%
)
Brent Oil
71.25
(
0.00%
)
Bitcoin
90,720.27
(
0.14%
)
Post# of 2350266
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

bobky

Send PM Follow Ignore
Followers 120
Posts 32706
Boards Moderated 2
Alias Born 01/30/2001

bobky

Member Level

Re: None

Friday, 03/08/2024 6:26:57 PM

Friday, March 08, 2024 6:26:57 PM

Post# of 2350266
AMLX. Some info on the 85% selloff today. @$AMLX Mizuho Securities analyst Graig Suvannavejh kept his buy rating on Amylyx stock.

He noted the firm is still testing Relyvrio — under the test name AMX0035 — in patients with Wolfram syndrome and progressive supranuclear palsy. Wolfram syndrome is a genetic condition associated with childhood-onset insulin-resistant diabetes and hearing loss. Progressive supranuclear palsy is a rare condition that affects walking, balance and eye function.

Amylyx says it now expects to have the results of its study in Wolfram syndrome patients in the second quarter.

We need your picks at 10 to 100 baggers board - http://investorshub.advfn.com/boards/board.aspx?board_id=10355

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up